320 related articles for article (PubMed ID: 25970639)
1. Warfarin pharmacogenetics in the era of new oral anticoagulants.
Wright GE
Clin Genet; 2015 Aug; 88(2):135-6. PubMed ID: 25970639
[No Abstract] [Full Text] [Related]
2. Pharmacogenomic testing and response to warfarin.
Wu AH
Lancet; 2015 Jun; 385(9984):2231-2. PubMed ID: 25769360
[No Abstract] [Full Text] [Related]
3. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
[No Abstract] [Full Text] [Related]
4. [The ENGAGE AF-TIMI 48 study].
Rubboli A; Colonna P
G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
[No Abstract] [Full Text] [Related]
5. Should patients on vitamin K antagonists be treated differently?
Pokorney SD; Granger CB
Eur Heart J; 2015 Jun; 36(23):1431-3. PubMed ID: 25694462
[No Abstract] [Full Text] [Related]
6. Edoxaban (Lixiana°).
Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
[No Abstract] [Full Text] [Related]
7. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
Plitt A; Giugliano RP
Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
[No Abstract] [Full Text] [Related]
8. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
9. [Large studies of NOAC shows good and safe stroke protection].
Hijazi Z; Oldgren J
Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
[No Abstract] [Full Text] [Related]
10. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
11. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
Plitt A; Ezekowitz MD; De Caterina R; Nordio F; Peterson N; Giugliano RP;
Clin Cardiol; 2016 Jun; 39(6):345-6. PubMed ID: 27028520
[No Abstract] [Full Text] [Related]
12. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Holden A; Azimi N; Forest CP
JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
15. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy and safety of edoxaban in non-valvular atrial fibrillation].
Szegedi A; Csanádi Z
Orv Hetil; 2018 Mar; 159(12):466-469. PubMed ID: 29552925
[TBL] [Abstract][Full Text] [Related]
17. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen J; Zhuang X; Long M; Su C; Wang L
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]